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Abstract
Background: Nasopharyngeal carcinoma associated gene 6 (NGX6) is down-regulated in most colon cancer cell lines 
and tumor tissues when compared with their normal tissue samples. As a novel suppress tumor gene, it could inhibit 
colon cancer cell growth and cell cycle progression. However, little is known about the transcriptional mechanisms 
controlling NGX6 gene expression. Recent findings suggest that epigenetic inactivation of multiple tumor suppressor 
genes plays an important role in the tumorigenesis of colorectal carcinoma (CRC). In this study, we explored the role of 
DNA methylation in regulation of NGX6 transcription.
Methods: In the present study, we cloned the NGX6 promoter with characteristics of a CpG island by luciferase 
reporter assay. Then, the CpG methylation status around the NGX6 promoter region in colon cancer cell lines and 
colorectal tumor tissues was examined by methylation-specific PCR and bisulfite DNA sequencing. Finally, 5-Aza-2'-
deoxycytidine (5-Aza-dC) treatment was used to confirm the correlation between NGX6 promoter methylation and its 
gene inactivation.
Results: The sequence spanning positions -157 to +276 was identified as the NGX6 promoter, in which no canonical 
TATA boxes were found, while two CAAT boxes and GC boxes were discovered. Methylation status was observed more 
frequently in 40 colorectal cancer samples than in 40 adjacent normal mucosa samples (18/40 versus 7/40; P < 0.05). 
An analysis correlating gene methylation status with clinicopathological cancer features revealed that dense 
methylation of the NGX6 promoter was associated with colorectal cancer patients age (P < 0.05). Moreover, a trend was 
shown toward metastasis status and primary site in colorectal carcinomas with NGX6 promoter methylation (p = 0.056 
and P = 0.067, respectively). In addition, 5-Aza-dC could induce NGX6 mRNA expression and NGX6 promoter 
demethylation in HT-29 cells.
Conclusions: Down-regulation of NGX6 gene is related to the promoter methylation. DNA methylation of NGX6 
promoter might be a potential molecular marker for diagnosis or prognosis, or serve as a therapeutic target.
Backgroud
Colorectal cancer (CRC) is one of the most common neo-
plasms all over the world. In addition to multiple genetic
alterations, it is now recognized that the development
and progression of CRC is associated with epigenetic
mechanisms, especially DNA methylation. The methyla-
tion of the cytosine residues in CpG-rich sequences (CpG
island) located in the promoter regions of genes regulat-
ing cell proliferation, apoptosis, and DNA repair [1,2].
Determination of epigenetic events is a strong candidate
for early detection of disease, since regulation of gene
expression by aberrant DNA methylation is a well-char-
acterized event in tumor biology, and is extensively
described for CRC.
NGX6 is a novel EGF-like domain-containing gene
identified by a location candidate cloning strategy [3]. Its
mRNA expression level in nasopharyngeal carcinoma tis-
sues was significantly lower than in normal nasopharyn-
geal epithelial tissues [4]. NGX6 was also down-regulated
in colorectal carcinomas, and the frequency of down-reg-
ulation of NGX6 in colorectal carcinoma tissues with
lymph node or distance metastasis (15/16) was signifi-
cantly greater than in patients without metastasis (25/34)
(P < 0.05) [5]. Indeed, over-expression of NGX6 gene in
HT-29 cells can effectively inhibit cell growth and cell
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Page 2 of 10cycle progression from G1 to S phase by transcriptional
regulation of some key cell cycle related genes [6]. Recent
studies show that NGX6 gene can reduce tumor forma-
tion and tumor size in nude mice by down-regulating the
EGFR/K-ras/JNK/c-Jun/cyclin D1 and Wnt/beta-catenin/
TCF/LEF signal pathways [7-10]. Therefore, the loss of
NGX6 function may be an important event in the pro-
gression of CRC and act as a novel candidate for tumor
suppression. However, little is known about the down-
regulation of NGX6 gene in CRC.
In the present study, we investigated whether the
NGX6 gene in colorectal cancer was regulated by epige-
netic mechanisms such as DNA methylation. Firstly, we
cloned the NGX6 promoter with characteristics of a CpG
island. Then, CpG methylation status around the NGX6
promoter region in colon cancer cell lines and tumor tis-
sues was examined by methylation-specific PCR and
bisulfite DNA sequencing. In order to demonstrate a
functional association between NGX6 promoter methy-
lation and its gene down-expression, we performed DNA
demethylation analysis with colon cancer cell line HT-29
using methylation-specific PCR, RT-PCR and real-time
PCR.
Methods
Cell lines and tumor tissues
Human colon carcinoma cell lines HT-29 and SW480
were from American Type Culture Collection (ATCC,
Rockville, MD) cell bank. Cos7 cells were provided by the
Cancer Research Institute, Xiangya School of Medicine,
Central South University (Human, P.R. China). All cells
were cultured in RPMI1640 medium containing 10%
heat-inactivated fetal bovine serum (FBS) and incubated
at 37°C in a humidified incubator containing 5% CO2.
Fresh colorectal cancer tissues and adjacent normal
colorectal tissues were obtained from patients treated by
primary surgery for colorectal cancer at Third Xiangya
hospital surgery department (Hunan, People's Republic of
China). All patients gave informed consent for the study
to retain and analyze their tissue for research purposes.
The samples were snap-frozen immediately following
resection and stored in liquid nitrogen until processing.
The 19 male and 21 female were aged from 18 to 81 years
(mean 54.7 ± 15.1 years). For the colorectal portion, we
obtained approval from the Ethic Committee of Central
South University.
Cloning and analysis of the NGX6 5'upstream regulatory 
region
The NGX6 promoter region in the 5' flanking region was
predicted using the PromoterInspector and FirstEF pro-
grams. The CpG island was found using CpGplot of the
European Molecular Biology Open Software Suite. To
obtain the 5' flanking region of the NGX6 gene, PCR
amplification on human genomic DNA (forward primer
5'-CGAGCCCAGAGGGTTTACTT-3', reverse primer
5'-GCCTCAATCTTCCCTGCTTC-3') was preformed in
a 50-μl reaction mixture. After an initial denaturation
step at 94°C for 10 min, the PCR reactions were carried
out for 30 cycles at 94°C for 30 sec, 58°C for 1 min, 72°C
for 2 min, with a final extension of 10 min at 72°C. The
PCR product was purified using a Gel Purification Kit
and cloned into the T/A cloning vector pGEM T-Easy
(Promega). Positive clones of pT/A -357/+769 were iso-
lated and sequenced.
Luciferase-reporter plasmid constructs and assay
All NGX6 promoter fragments were cloned into pGL3
enhancer vector (Promega). Construct naming is based
on the positions of the promoter fragments. Five deletion
constructs of the NGX6 promoter region were created.
These progressive deletion constructs (pGL3 -357/+769,
pGL3 -357/+276, pGL3 +276/+769, pGL3 -357/-159,
pGL3 -159/+276), originating from the construct pT/A -
357/+769, were amplified by PCR using the primers listed
in Table 1. All the primers included 9-bp non comple-
mentary extensions capable of generating KpnI or Hin-
dIII restriction sites. The promoter fragments were then
subcloned into the KpnI/HindIII sites of pGL3 enhancer
vector and sequenced.
Transfections were performed with Lipofectamine
2000 (Invitrogen, CarIsbad, CA); 5 × 105 cells were seeded
in each well of 12-well tissue culture plate 24 h prior to
transfection. The cells were transfected with 1 μg of vari-
ous NGX6 promoter constructs, pGL3-control plasmid,
or pGL3-enhancer plasmid, and 0.5 μg β-galactosidase
vector for normalizing transfection efficiency per well
according to manufacturer's instructions. Firefly
luciferase activity was measured in cell lysates 48 h after
transfection by using Luciferase Assay Kit (Promega). β-
Galactosidase activity was measured in cell lysates by the
β-galactosidase Enzyme Assay System (Promega). Experi-
ments were repeated at least three times with three repli-
cates per sample for each experiment. Results are
normalized against β-galactosidase activity.
Genomic DNA extraction and Bisulfite modification
Genomic DNA from cells and tissues was prepared using
a DNA Extraction Kit (TaKaRa) according to the manu-
facturer's instructions. Five hundred nanograms of
genomic DNA was modified and purified using an EZ
DNA Methylation-Gold Kit (ZYMO REAEARCH), fol-
lowing the manufacturer's protocol. Modified DNA was
used immediately or stored at -80°C for up to six months.
Methylation-Specific PCR analysis of NGX6 promoter
The methylation-specific PCR primers were designed
according to the promoter-active DNA sequence using
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fied by two different primer pairs specific to the unmeth-
ylated (u) and methylated (M) NGX6 promoter
sequences, respectively. Methylation-specific primers
(forward) 5'-AGGGATTAATCGAGTCGGTC-3',
(reverse) 5'-ATAACCTCCGATATCCTCGC-3'. Unmeth-
ylation-specific primers (forward) 5'-GGTTTTATTGA-
TAGGGATTA-3', (reverse) 5'-TATCCTCACAAACC
CAAA-3'. PCR amplification was performed for a total of
38 cycles with an annealing temperature of 65°C and
55°C, respectively. Non-methylated and methylated
human DKO DNA (ZYMO RESEARCH) was used as
negative and positive control, respectively. Methylation-
specific PCR products were analyzed by a 2% agarose gel
and stained with ethidium bromide.
NGX6 promoter methylation analysis by Sodium Bisulfite 
Sequencing
According to the result of CpGplot program, a 385-bp
sequence which covers the whole sequence of MSP prod-
uct was amplified. The primers were forward 5'-TGT-
GAGGATAGGGTTTTTTTGAGAT-3' and reverse 5'-
CACCCCCRAAAAATAACCTC-3'. The PCR amplifica-
tion was performed for a total of 38 cycles with annealing
temperature of 60°C. PCR products were gel-purified and
cloned into the T/A cloning vector pGEMT-Easy (Pro-
mega). Ten subclones were isolated and identified by
double digestion and sequencing.
5-Aza-2'-deoxycytidine treatment
Human colon carcinoma cells HT-29 was grown for 5
days in the presence of various concentrations of 5-Aza-
dC (0, 0.625, 1.25, 2.5, 5, and 10 μM). Fresh drug was add
every 24 h. RNA and genomic DNA were separately iso-
lated.
Reverse transcription PCR and Real-time PCR
RNA was isolated from harvested cells with Trizol (Invit-
rogen) reagent and then treated with DNase (Roche) to
eliminate possible contaminated DNA. Reverse tran-
scription of the RNA was performed according to the
instructions of Promega. 2 μl cDNA was used for each
PCR using NGX6-special primers. The forward primer
was 5'-AGAACCGCCATCCCTT-3', and the reverse
primer was 5'-CACCTCGTGAGTCAAGCA-3'. The
primers for GAPDH were as follows: forward, 5'-
AGGTCGGAGTCAACGGATTTG-3'; reverse, 5'-
GTGATGGCATGGACTGTGGT-3'. The GAPDH prim-
ers were added to the PCR at the end of the tenth cycle as
control experiments. Ten microliters of each reaction was
then run on 2% agarose gel and stained with ethidium
bromide.
Then quantification of relative Quantification of rela-
tive transcript levels for NGX6 was performed using the
BIO-RAD IQ™ 5 Muticolor Real Time PCR Detection
System. cDNA samples were amplified with SYBR® Pre-
mix Ex Taq™. The thermal cycling profile consisted of ini-
tial denaturation at 95°C for 30 s and 40 cycles at 95°C for
5 s, 54°C for 15 s, and 72°C for 30 s. Each sample was pro-
cessed in triplicate. The expression level of NGX6 was
normalized to GAPDH using IQ5 software.
Statistical analysis of clinicopathological patient data
Statistical analyses were carried out using SPSS 16.0.
Comparisons of categorical variables were made using χ2
test or Fisher's exact test as appropriate. Differences were
considered statistically significant when P-values were
below 0.05.
Table 1: Primer pairs used for generating NGX6 promoter 
construct pGL3 -357/+769, pGL3-357/+276, pGL3 +276/
+769, pGL3 -357/-159, pGL3 -159/+276.
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Cloning and bioinformatic analysis of the NGX6 5'upstream 
regulatory region
To clone the NGX6 promoter region, a database search
against the human genomic DNA database using NGX6
(Genbank accession AF188239) as query http://
www.ncbi.nlm.nih.gov/BLAST was performed to reveal
the 5' upstream sequence of the NGX6 gene. Several bio-
informatics tools were used to identify the potential pro-
moter region of the NGX6 gene. A 248-bp region
spanning positions -157 to +91 was identified as the
potential promoter region of the NGX6 gene using Pro-
moterInspector [11], whereas two regions located from -
257 to +313 and -163 to +407 were identified as the
NGX6 promoter using FirstEF program [12]. The 5'
upstream sequence of the NGX6 gene was submitted for
analysis to the CpGplot program [13]. Typical CpG
islands were defined as ≥ 200 bp of sequence that had a
C+G content of ≥ 50% and a value of >0.6 for the ratio
(CpG observed)/(CpG expected) [14]. A CpG island that
spanned positions -107 to +299 was detected using the
program (Figure 1). Finally, a genomic DNA fragment
that spanning positions -357 to +769 (the genomic
sequence number 35819222 of the NGX6 gene is defined
as +1) was amplified by PCR. The fragment was then
cloned into the T/A cloning vector pGEM-T-Easy (Pro-
mega).
Identification of NGX6 proximal promoter
In order to identify the proximal promoter region of
NGX6 gene, four constructs of progressive deletion were
generated and cloned to the upstream of the luciferase
reporter gene in the pGL3-enhancer vector (Promega).
Transient transfection experiments were carried out
using promoter deletion constructs spanning positions -
357 to +769. Plasmid pGL3-357/+276, pGL3+276/+769,
pGL3 -357/-159 and pGL3-159/+276 were transfected
with Lipofectamine 2000 (Invitrogen) into Cos7 and HT-
29 cells, respectively. The luciferase activity driven by
NGX6 promoter constructs was measured 48 h after
transfection. Expression levels were corrected for variable
transfection efficiencies by cotransfection with a plasmid
directing the β-galactosidase expression.
As shown in Figure 2, in Cos7 and HT-29 cells, the
reporters driven by the shorter 433-bp fragment (pGL3-
157/+276) which should contain the core promoter,
showed as high luciferase expression as the SV40 pro-
moter of pGL3-control. Luciferase expression driven by
the construct pGL3 +276/+769 and pGL3 -357/-159
exhibited as extremely low as pGL3-enhancer. Thus, the
sequence spanning positions -159 to +276 was identified
as a promoter. MethPrimer Program analysis showed that
the NGX6 promoter region had high G/C content and
characteristic of a CpG island [15]. In addition, no canon-
ical TATA boxes, but two CAAT boxes were found in this
promoter region by the MatInspector program (data not
shown).
Frequent aberrant methylation of NGX6 promoter in 
colorectal cancer cell lines and tissues
Epigenetic modification is a frequent mechanism of inac-
tivation of tumor suppressor genes in colorectal cancer
[16]. To clarify the mechanism of NGX6 gene inactiva-
tion in colorectal cancer cells and tissues, methylation-
specific PCR was used to examine the methylation status
of the NGX6 promoter. Both HT-29 and SW480 cell lines
showed methylation of the NGX6 promoter (Figure 3A).
Figure 1 Bioinformatics analysis of the NGX6 5' upstream regulatory region. Schematic representation of the putative NGX6 promoter region 
and CpG island. The region showing the putative promoter activity and the CpG island are shown as a dark blue box, two red box, and a purple box, 
respectively. The genomic sequence number 35819222 of the NGX6 gene is defined as +1.
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Figure 2 Deletion analysis of the NGX6 promoter. (A) Schematic illustration of deletion constructs of NGX6 promoter. (B)Luciferase activity of the 
deleted constructs in Cos7 and HT-29 cells. PGL3-enhancer, PGL3-control and NGX6-promoter deleted constructs were transfected into Cos7 and HT-
29 cells. All of the constructs were cotransfected with β-galactosidase vector for normalizing transfection efficiency. Data are the meas ± SD of three 
independent experiments. All the transfection experiments were repeated at least three times.
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Figure 3 Methylation of the NGX6 promoter in colorectal cancer. (A) Methylation of the NGX6 promoter in colon cancer cells HT-29 and SW480. 
(B) DNA from 40 colorectal cancer tissue (T) and 40 adjacent normal colorectal tissues (N) were bisulfite-modified and analyzed for methylaion of the 
NGX6 promoter by methylation-specific PCR analysis. "DL": DNA marker2000; "P": positive methylated control; "N": negative unmethylated control; "M": 
methylated NGX6; "U": unmetylated NGX6.
Table 2: NGX6 promoter methylation frequency in colorectal cancer and adjacent normal mucosa.
Methylation status
variable n Absent Present
Colorectal cancer 40 22 (55%) 18 (45%)
Adjacent normal mucosa 40 33 (82.5%) 7 (17.5%)
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Table 3: Clinicopathological parameters compared to NGX6 promoter methylation analyed by Chi-square Test or Fisher' s 
Exact Test.
Methylation status
Variable Absent Present P-value
Sex
Male 9(47.4%) 10(52.6%) 0.369
Female 13(61.9%) 8(38.1%)
Age
<65 Years 11(40.7%) 16(59.3%) 0.008
≥ 65 Years 11(84.6%) 2(15.4%)
Dukes stage





Negative 14(70.0%) 6(30.0%) 0.056
Positive 8(40.0%) 12(60.0%)
Primary site
Colon 7(38.9%) 11(61.1%) 0.067
Rectum 15(68.2%) 7(31.8%)
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promoter in colon cancer cell lines reflects an epigenetic
event occurring in primary colorectal cancer tissues, we
further examined the NGX6 promoter mathylation status
in the 40 pairs of colorectal cancers and adjacent normal
colorectal mucosa using methylation-specific PCR (some
are shown in Figure 3B). The methylated PCR product
was detected in 18/40 (45%) cancer samples and 7/40
(17.5%) adjacent normal samples (Table 2).
To clarify whether the NGX6 methylation status of the
colorectal samples was correlated with clinicopathologi-
cal features of colorectal cancer patients, univariate anal-
yses were carried out to correlate the methylation status
of the NGX6 promoter with various clinicopathological
parameters. As shown in Table 3, only methylation of the
NGX6 promoter was found to correlate with age in col-
orectal cancer (p < 0.05).
To determine a more detailed map of the methylation
in the NGX6 promoter, we performed bisulfite sequenc-
ing around the promoter region of the NGX6 gene in
colon cancer cell lines and some of the colorectal cancer.
Specific primers without CpG sites were used to amplify
the region spanning position -233 to +150. The sequence
including 34 CpG sites was showed in Figure 4. Bisulfite
sequencing of 10 individual clones of PCR products from
primary colon cancer biopsies (T38) and cell lines (HT-29
and sw480) revealed densely methylated CpGs within the
promoter region compared to normal colon tissue (N38).
5'-Aza-dC augmented endogenous mRNA and reversed the 
methylation status of NGX6 promoter in colon cancer cells
In order to clarify the functional association between
NGX6 promoter methylation and its aberrant expression
in CRC, a DNA demethylating agent, 5-Aza-dC was used
to treat HT-29 cells. After 5 days treatment, we isolated
mRNA and genomic DNA from the cells, and then
detected NGX6 mRNA re-expression in these cells using
RT-PCR assay (Figure 5A) and Real-time PCR (Figure
5B). NGX6 expression increased with increasing dosage
of 5-Aza-dC. NGX6 expression was higher when induced
by 2.5 μM 5-Aza-dC. To confirm that reactivation of
NGX6 mRNA expression in HT-29 cell line was caused
by demethylation of the NGX6 promoter, methylation-
specific PCR was used to detect methylation status
changes in the NGX6 promoter in HT-29 cell lines after
5-Aza-dC treatment. The results showed that 2.5 μM 5-
Aza-dC could reverse the methylation of NGX6 pro-
moter in HT-29 cells (Figure 5C).
Discussion
As a candidate tumor suppressor gene, down-regulation
of the NGX6 gene has been shown to be critical to the
pathogenesis of colorectal cancer [17,18]. However, the
mechanism responsible for the inactivation of NGX6
gene in colorectal cancer has not been investigated. To
delineate the control mechanisms of NGX6 gene expres-
sion, we reported, for the first time, the cloning and func-
tional characterization of the NGX6 promoter.
In this study, we cloned and characterized 1126 bp (-
357 to +769) of the 5' genomic region of NGX6 gene,
which exhibits promoter activity as SV40 promoter. In
order to define the proximate regulatory regions in the
NGX6 promoter, we generated a series of 5'-deleted con-
structs and transfected into Cos7 and HT-29 cells,
respectively. The results of luciferase expression indi-
cated that a 433-bp region (-157 to +276) was found to be
necessary for the transcriptional activity of the NGX6
gene, which suggested that we have found a function of
the NGX6 promoter.
As the result of bioinformational analysis, the func-
tional NGX6 promoter region is a TATA-less, GC-rich
promoters and has several CAAT boxes. Meanwhile,
there is a CpG island in the region of NGX6 promoter,
and its function has remained undetermined. It is well
known that aberrant promoter hypermethylation is
thought to contribute to carcinogenesis by inactivating
tumor suppressor genes. Many tumor suppressor genes
silencing described in colorectal cancers have been linked
to promoter hypermethylation such as p16, MLH1, TSP-1
and APC [19-22]. Here, the NGX6 promoter was found
to be methylated in colon cancer cell line HT-29.
The prevalence of NGX6 promoter methylation in col-
orectal cancers was 45% (18/40) compared with 17.5% (7/
40) in normal colorectal mucosa (P < 0.008). This result
suggested that the aberrant methylation of the NGX6
gene was frequent in colorectal cancers. Then the corre-
lation between the methylation status and the clinico-
pathological findings in 40 colorectal cancer tissues was
evaluated. In the study, a significant difference was
observed in age (p = 0.008). Moreover, a trend was shown
toward metastasis status and primary site in colorectal
carcinomas with NGX6 promoter methylation (p = 0.056
and P = 0.067, respectively). And bisulfite sequence anal-
ysis of the CpG islands around NGX6 promoter indicate
that dense methylation of CpG sites in colon cancer cell
lines and colorectal cancer tissues compared with normal
colorectal tissues. NGX6 promoter methylation may
serve as a biomarker for diagnosis. Since the ability of
invasion and metastasis is closely related to prognosis in
colorectal cancer, NGX6 methylation may also be a bio-
marker for prognosis. Of course, all of these hypotheses
must be further studied using a large number sample
analysis.
Treatment of HT-29 cells with 5-Aza-dC restored
NGX6 expression suggests that aberrant hypermethyla-
tion of the promoter is directly responsible for ranscrip-
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These methylated CpG dinucleotides lie in regions that
can inhibit NGX6 gene transcription through one of two
mechanisms. First, transcription factor binding may be
inhibited by methylated CpG dinucleotides. And second,
proteins that recognize methyl-CpG can elicit the repres-
sive potential of methylated DNA [23]. The methylase
inhibitor can reverse NGX6 expression in colorectal can-
cer, and it is possible to restore its function as tumor sup-
pressor gene at some a degree. This shows that NGX6
may be a potential target for therapy.
Conclusions
In summary, through methylation-specific PCR, bisulfite
sequencing and demethylation treatment, we have estab-
lished that loss of NGX6 expression in colorectal cancers
may be due in part to methylation of CpG sites within the
NGX6 promoter. NGX6 promoter methylation may be
used as a potential biomarker for diagnosis and progno-
sis, or a useful target for therapy.
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Figure 4 Bisulfite sequence analysis of NGX6 promoter. Methyla-
tion status of CpG sites around the NGX6 promoter region were ana-
lyzed in colon cancer cell lines HT-29 and SW480, colon cancer tissue 
(T38) and adjacent normal colorectal tissues (N38). Region spans -233 
to +150 including 34 CpG sites. Each row represents an individual sub-
clone. White circles represent unmethylated CpGs. Black circles repre-
sent methylated CpGs.
Figure 5 5-Aza-dC induced the expression of NGX6 in HT-29 cells. 
(A) Colon cancer cell line HT-29 was treated with six different doses of 
5-Aza-dC (0.625, 1.25, 2.5, 5.0 and 10 μM), as indicated above each lane, 
for five days. Total RNA was isolated from control, and treated cells 
were then analyzed by RT-PCR. (B) NGX6 mRNA level was analyzed by 
real-time PCR after 5-Aza-dC treament. (C). colon cancer cell line HT-29 
was treated with 2.5 μM 5-Aza-dC for five days. DNA was isolated and 
bisulfite-modified, and then analyzed for methylaion of the NGX6 pro-
moter by methylation-specific PCR analysis. "DL": DNA marker 2000; 
"M": methylated NGX6; "U": unmetylated NGX6.
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